Data on 37 countries reveals widespread failure to follow latest international recommendations for policies on prevention, diagnosis, and treatment.

120,707 people signed petitions urging the corporation to drop the price.

As the world grapples with the global pandemic of coronavirus, Doctors Without Borders/Médecins Sans Frontières (MSF) is concerned for vulnerable groups worldwide, like people with tuberculosis (TB), whose lungs are often damaged and immune systems weakened.

Médecins Sans Frontières (MSF) updated two of its technical briefs, A rapid TB test for people living with HIV and Making the switch.

Treatment Action Group, Médecins Sans Frontières and Health GAP conducted a webinar on 22 January 2020 on how to engage in PEPFAR Country Operational Plans (COPs) advocacy and promote the prioritization of interventions that address HIV co-infections and AIDS.

Group protests at New York Stock Exchange as Johnson & Johnson releases earnings report.

Treatment Action Group, Médecins Sans Frontières and Health GAP will host a webinar on 22 January 2020 on how to engage in PEPFAR Country Operational Plans (COPs) advocacy and promote the prioritization of interventions that address HIV co-infections and AIDS.

The high cost of GeneXpert tests for TB leaves open a critical gap in the diagnosis of TB and fails to consider volume of sales and public investments in the development of GeneXpert.

Newer medicines for drug-resistant TB are desperately needed, but barriers to access, including high prices, keep them out of reach for most people around the world. 

Pretomanid is just one part of a regimen of multiple drugs that people need. MSF has been calling for the price of a complete DR-TB treatment course to be no higher than $500 per person.